Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

Abstract:

:The wt1 gene is located on chromosome 11p13 and encodes a zinc finger motif-containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues as well as in a few human malignancies including acute leukemias. Using RT-PCR, we found wt1 gene expression in blast cells of the majority of 150 acute leukemia patients. Particularly, the wt1 transcript was detected in 12 of 14 (86%) pre-pre-B-ALL patients, in 33 of 41 (80%) cALL patients, in 23 of 31 (74%) T-ALL patients, and in 53 of 57 (93%) AML patients. Additionally, mononuclear cells from CML patients expressed the wt1 gene only when diagnosed with blast crisis. In contrast to acute human leukemias, mononuclear cells from reactive bone marrow (n = 4), and peripheral blood of healthy volunteers (n = 20), as well as normal peripheral CD34+ hematopoietic progenitors (n = 6) did not express the wt1 gene at detectable levels. Using the anti-WT1 MoAb 6F-H2 in an immunofluorescence assay on single cell level, we found the translated WT1 protein only in nuclei of leukemia blast cells but not in nuclei of normal CD34+ hematopoietic progenitor cells. Blast cells of 12 of 20 leukemia patients (60%) all tested positive for the wt1 gene expression by RT-PCR displayed a strong nuclear immunofluorescence. Its expression in the majority of human acute leukemias but not in normal mononuclear blood cells and normal CD34+ hematopoietic progenitors qualifies the wt1 gene transcript as a 'pan-acute leukemic' marker probably useful in monitoring minimal residual disease after chemotherapy and in detecting leukemic blast cells in purged or unpurged hematopoietic stem cell preparations intended to be used for autologous bone marrow transplantation.

journal_name

Leukemia

journal_title

Leukemia

authors

Menssen HD,Renkl HJ,Rodeck U,Maurer J,Notter M,Schwartz S,Reinhardt R,Thiel E

subject

Has Abstract

pub_date

1995-06-01 00:00:00

pages

1060-7

issue

6

eissn

0887-6924

issn

1476-5551

journal_volume

9

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Complex landscape of alternative splicing in myeloid neoplasms.

    abstract::Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-1002-y

    authors: Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

    更新日期:2020-08-04 00:00:00

  • Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia.

    abstract::It has been proposed that adoptive immunotherapy, for the treatment of relapsed AML, with cytotoxic T lymphocytes which show a relative specificity for the leukemic cells may have the advantage of maximizing the beneficial anti-leukemic effect whilst minimizing the probability of graft-versus-host disease. In this stu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402013

    authors: Woiciechowsky A,Regn S,Kolb HJ,Roskrow M

    更新日期:2001-02-01 00:00:00

  • Anti-angiogenic activity of the purine analog 6-thioguanine.

    abstract::The antimetabolite 6-thioguanine (6-TG) is utilized in the management of acute myelogenous leukemia (AML). Angiogenesis is a possible therapeutic target in hematologic tumors. Thus, we addressed the possibility that 6-TG may also act as an anti-angiogenic molecule. 6-TG inhibited endothelial cell proliferation trigger...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402646

    authors: Presta M,Belleri M,Vacca A,Ribatti D

    更新日期:2002-08-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract::Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Griffiths SD,Cawley JC

    更新日期:1988-06-01 00:00:00

  • Heterogeneity in protein patterns of cells from terminal blast crisis in chronic granulocytic leukemia: discrimination between lymphatic and myeloid lineages.

    abstract::Terminal blast crisis cells of chronic granulocytic leukemia are biochemically distinct. Triton-X-114 detergent phase lysates revealed that myeloid types express predominantly proteins of a 24 kd apparent molecular weight range, whereas lymphatic types do not express these molecules but a 55 kd protein band. These bio...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Doxiadis I,Dölken P,Schneider M,Wernet P,Grosse-Wilde H

    更新日期:1988-12-01 00:00:00

  • Expression of the LH2 gene in chronic myeloid leukaemia cells.

    abstract::The LH2 gene encodes a putative transcription factor containing two N-terminal LIM and one C-terminal HOX domains. The LH2 locus was mapped to 9q33-34.1, centromeric to the ABL gene. In a recent report, it was suggested that high levels of LH2 expression are consistently observed in chronic myeloid leukemia (CML) pati...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Al-Jehani F,Hochhaus A,Spencer A,Goldman JM,Melo JV

    更新日期:1996-07-01 00:00:00

  • Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

    abstract::This corrects the article DOI: 10.1038/leu.2017.9. ...

    journal_title:Leukemia

    pub_type: 杂志文章,已发布勘误

    doi:10.1038/leu.2017.348

    authors: Schütz C,Inselmann S,Saussele S,Dietz CT,Müller MC,Eigendorff E,Brendel CA,Metzelder SK,Brümmendorf TH,Waller C,Dengler J,Goebeler ME,Herbst R,Freunek G,Hanzel S,Illmer T,Wang Y,Lange T,Finkernagel F,Hehlmann R,Hu

    更新日期:2018-04-01 00:00:00

  • Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

    abstract::It has become apparent that regulation of protein translation is an important determinant in controlling cell growth and leukemic transformation. The phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homologue deleted on chromosome ten (PTEN)/Akt/mammalian target of rapamycin (mTOR) pathway is often implicated i...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2011.46

    authors: Martelli AM,Evangelisti C,Chappell W,Abrams SL,Bäsecke J,Stivala F,Donia M,Fagone P,Nicoletti F,Libra M,Ruvolo V,Ruvolo P,Kempf CR,Steelman LS,McCubrey JA

    更新日期:2011-07-01 00:00:00

  • Adult T cell leukemia cell lines that originated from primary leukemic clones also had a defect of expression of CD3-T cell receptor complex.

    abstract::Surface phenotypes and genotypes of six T cell lines established from four patients with adult T cell leukemia (ATL) were compared with those of fresh ATL cells. The surface antigen densities of CD3 and T cell receptor (TCR) complex examined by OKT3 and WT-31 mAbs on fresh ATL cells were low. But three IL-2-dependent ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Shirono K,Hattori T,Matsuoka M,Matsushita S,Asou N,Takatsuki K

    更新日期:1988-11-01 00:00:00

  • Imatinib sensitizes CLL lymphocytes to chlorambucil.

    abstract::The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403247

    authors: Aloyz R,Grzywacz K,Xu ZY,Loignon M,Alaoui-Jamali MA,Panasci L

    更新日期:2004-03-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract::Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.283

    authors: Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期:2011-03-01 00:00:00

  • Significance of chemokine receptor expression in aggressive NK cell leukemia.

    abstract::Natural killer (NK) cell-type lymphoproliferative diseases of granular lymphocytes can be subdivided into aggressive NK cell leukemia (ANKL) and chronic NK cell lymphocytosis (CNKL). One reason for the poor outcome in ANKL is leukemic infiltration into multiple organs. The mechanisms of cell trafficking associated wit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403732

    authors: Makishima H,Ito T,Asano N,Nakazawa H,Shimodaira S,Kamijo Y,Nakazawa Y,Suzuki T,Kobayashi H,Kiyosawa K,Ishida F

    更新日期:2005-07-01 00:00:00

  • Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.

    abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400858

    authors: Coleman S,Throp D,Fisher J,Bailey-Wood R,Lim SH

    更新日期:1997-12-01 00:00:00

  • De novo gene mutations in normal human memory B cells.

    abstract::In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0289-4

    authors: Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

    更新日期:2019-05-01 00:00:00

  • Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma.

    abstract::Osteolysis resulting in extensive bone damage is a major clinical manifestation of patients with multiple myeloma (MM). The mechanisms of bone resorption in MM are incompletely understood. The final pathway is the generation of activated osteoclasts within bone marrow (BM) microenvironment. To investigate the mechanis...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gregoretti MG,Bergui L,Aragno M,Cremona O,Marchisio PC,Caligaris-Cappio F

    更新日期:1995-08-01 00:00:00

  • A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

    abstract::Retinoids have significant antiproliferative effect against chronic myelogenous leukemia (CML) cells in vitro. We conducted a pilot study to investigate the clinical effect of all-trans retinoic acid (ATRA) in patients with CML. Thirteen patients with Philadelphia chromosome (Ph)-positive CML in late chronic phase (n=...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400682

    authors: Cortes J,Kantarjian H,O'Brien S,Beran M,Estey E,Keating M,Talpaz M

    更新日期:1997-07-01 00:00:00

  • P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia.

    abstract::In order to further define the role of the MDR1 gene in acute myeloid leukemia (AML), we determined the association between the presence of P-glycoprotein on leukemic cells and the efficacy of therapy in patients with AML. Immunocytochemistry with monoclonal antibody C219 was performed to demonstrate the presence of P...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zöchbauer S,Gsur A,Brunner R,Kyrle PA,Lechner K,Pirker R

    更新日期:1994-06-01 00:00:00

  • Clonal instability preceding lymphoid blastic transformation of chronic myeloid leukemia.

    abstract::We have sought the presence of rearrangements of the immunoglobulin heavy chain gene locus in 13 patients with chronic myeloid leukemia (CML) in lymphoid blastic transformation (L-BT) using the polymerase chain reaction (PCR). The lymphoid nature of the transformation was confirmed by immunophenotyping and/or Southern...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400543

    authors: Spencer A,Vulliamy T,Kaeda J,Goldman JM,Melo JV

    更新日期:1997-02-01 00:00:00

  • Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.

    abstract::Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparabl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.267

    authors: Creutzig U,Zimmermann M,Bourquin JP,Dworzak MN,Kremens B,Lehrnbecher T,von Neuhoff C,Sander A,von Stackelberg A,Schmid I,Starý J,Steinbach D,Vormoor J,Reinhardt D

    更新日期:2012-04-01 00:00:00

  • IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells.

    abstract::Chimeric antigen receptor (CAR) T cell therapies lead to high clinical response rates in B cell malignancies, and are under investigation for treatment of solid tumors. While high systemic interleukin- (IL-) 6 levels are associated with clinical cytokine release syndrome (CRS), the role of IL-6 trans-signaling within ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01085-1

    authors: Jiang Z,Liao R,Lv J,Li S,Zheng D,Qin L,Wu D,Chen S,Long Y,Wu Q,Wang S,Lin S,Huang X,Tang Z,Shi P,Zhou H,Liu Q,Zhao R,Li Y,Jie Y,Wei W,Lai P,Du X,Cui S,Weinkove R,Liu P,Pei D,Yao Y,Li P

    更新日期:2020-11-09 00:00:00

  • Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.

    abstract::Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404172

    authors: Chng WJ,Santana-Dávila R,Van Wier SA,Ahmann GJ,Jalal SM,Bergsagel PL,Chesi M,Trendle MC,Jacobus S,Blood E,Oken MM,Henderson K,Kyle RA,Gertz MA,Lacy MQ,Dispenzieri A,Greipp PR,Fonseca R

    更新日期:2006-05-01 00:00:00

  • Effect of hyperthermia on both primary proliferation and self-renewal of human leukemic progenitor cells in vitro: its application to in vitro purging.

    abstract::Self-renewal, as defined by the capacity to yield new colonies following replating, is an important function of leukemic progenitors (L-CFU) to originate self-maintaining clones. In this work, we studied the effect of hyperthermia (41-44 degrees C) on the growth of human L-CFU derived primary colonies and of secondary...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Moriyama Y,Nikkuni K,Saito H,Aoki A,Kishi K,Takahashi M,Shibata A

    更新日期:1991-04-01 00:00:00

  • Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes.

    abstract::Human T cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T cell leukemia (ATL) transforms human T cells in vitro and in vivo. Tax, the major transactivator of HTLV-I is critical for the initial events involved in transformation, however, the later steps required for progression from an IL-2 dependent ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gartenhaus RB,Wang P

    更新日期:1995-12-01 00:00:00

  • BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

    abstract::Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.44

    authors: Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

    更新日期:2014-08-01 00:00:00

  • ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

    abstract::Disruption of pathways leading to programmed cell death plays a major role in most malignancies, including multiple myeloma (MM). ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/ap...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404719

    authors: Kline MP,Rajkumar SV,Timm MM,Kimlinger TK,Haug JL,Lust JA,Greipp PR,Kumar S

    更新日期:2007-07-01 00:00:00

  • Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.

    abstract::Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptos...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.357

    authors: Ding H,Peterson KL,Correia C,Koh B,Schneider PA,Nowakowski GS,Kaufmann SH

    更新日期:2017-07-01 00:00:00

  • Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.

    abstract::Recent studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple subclones. It is not known whether specific gene mutations typically occur in founding clones or subclones. We screened a panel of 94 candidate genes in a cohort of 157 patients with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.58

    authors: Walter MJ,Shen D,Shao J,Ding L,White BS,Kandoth C,Miller CA,Niu B,McLellan MD,Dees ND,Fulton R,Elliot K,Heath S,Grillot M,Westervelt P,Link DC,DiPersio JF,Mardis E,Ley TJ,Wilson RK,Graubert TA

    更新日期:2013-06-01 00:00:00

  • MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.

    abstract::Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403377

    authors: Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

    更新日期:2004-07-01 00:00:00

  • Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.

    abstract::Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders characterized by refractory cytopenias and susceptibility to leukemic transformation. On a subset of MDS patients with deletion of the long arm of chromosome 5 (del(5q)), lenalidomide exerts hematological and cytogenetic effects, but the ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.296

    authors: Matsuoka A,Tochigi A,Kishimoto M,Nakahara T,Kondo T,Tsujioka T,Tasaka T,Tohyama Y,Tohyama K

    更新日期:2010-04-01 00:00:00

  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract::RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0603-9

    authors: Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期:2020-03-01 00:00:00